INTRODUCTION: Presently, programmed death ligand 1 is the most commonly used biomarker to predict response to immune checkpoint inhibitors (ICIs) in NSCLC. Owing to its several limitations, there is continuous search for more precise and reliable markers. Frameshift mutations by insertion or deletion (fsindels) are suggested to induce more immunogenic tumor-specific neoantigens, conferring better response to ICIs. Positive correlation of fsindels with ICI response has been studied in melanoma and renal cell carcinoma. We investigated the implication of fsindels in the clinical outcomes and immune landscape of patients with NSCLC treated with ICIs. METHODS: We utilized The Cancer Genome Atlas data set to analyze tumor mutational burden, neoantigen burden, and immune landscape in relation to fsindel status. In addition, utilizing the clinical data from 122 patients treated with ICIs, we evaluated the influence of fsindels on disease response rates and survival outcomes. RESULTS: A positive correlation between fsindel burden and tumor mutational burden and activated CD4/CD8 T-cell infiltration was shown. Presence of fsindels was also associated with significant prolongation of progression-free survival in patients treated with ICIs (median 6.2 versus 2.7 months [p = 0.01]). In addition, significant differences in the overall response rates (26% versus 12% [p = 0.04]) and disease control rates (68% versus 48% [p = 0.02]) were observed in patients with fsindels. CONCLUSION: Our findings suggest that fsindels may have a predictive role for ICI response in NSCLC.
INTRODUCTION: Presently, programmed death ligand 1 is the most commonly used biomarker to predict response to immune checkpoint inhibitors (ICIs) in NSCLC. Owing to its several limitations, there is continuous search for more precise and reliable markers. Frameshift mutations by insertion or deletion (fsindels) are suggested to induce more immunogenic tumor-specific neoantigens, conferring better response to ICIs. Positive correlation of fsindels with ICI response has been studied in melanoma and renal cell carcinoma. We investigated the implication of fsindels in the clinical outcomes and immune landscape of patients with NSCLC treated with ICIs. METHODS: We utilized The Cancer Genome Atlas data set to analyze tumor mutational burden, neoantigen burden, and immune landscape in relation to fsindel status. In addition, utilizing the clinical data from 122 patients treated with ICIs, we evaluated the influence of fsindels on disease response rates and survival outcomes. RESULTS: A positive correlation between fsindel burden and tumor mutational burden and activated CD4/CD8 T-cell infiltration was shown. Presence of fsindels was also associated with significant prolongation of progression-free survival in patients treated with ICIs (median 6.2 versus 2.7 months [p = 0.01]). In addition, significant differences in the overall response rates (26% versus 12% [p = 0.04]) and disease control rates (68% versus 48% [p = 0.02]) were observed in patients with fsindels. CONCLUSION: Our findings suggest that fsindels may have a predictive role for ICI response in NSCLC.
Authors: Hyung-Don Kim; Min-Hee Ryu; Young Soo Park; Sun Young Lee; Meesun Moon; Yoon-Koo Kang Journal: Gastric Cancer Date: 2021-09-01 Impact factor: 7.370
Authors: Amir Mehrvarz Sarshekeh; Jumanah Alshenaifi; Jason Roszik; Ganiraju C Manyam; Shailesh M Advani; Riham Katkhuda; Anuj Verma; Michael Lam; Jason Willis; John Paul Shen; Jeffrey Morris; Jennifer S Davis; Jonathan M Loree; Hey Min Lee; Jaffer A Ajani; Dipen M Maru; Michael J Overman; Scott Kopetz Journal: Clin Cancer Res Date: 2021-01-07 Impact factor: 13.801
Authors: Robert J Motzer; Toni K Choueiri; David F McDermott; Thomas Powles; Yann-Alexandre Vano; Saurabh Gupta; Jin Yao; Celine Han; Ron Ammar; Simon Papillon-Cavanagh; Shruti S Saggi; M Brent McHenry; Petra Ross-Macdonald; Megan Wind-Rotolo Journal: J Immunother Cancer Date: 2022-03 Impact factor: 12.469